

Neurotech

27 July 2020

Neurotech commences profiling assays on Dolce proprietary cannabis strains, targeting autism and other neurological disorders

Highlights


- **NTI commences initial activities on cannabinoid profiling after its recent option to acquire an exclusive worldwide licence to use proprietary cannabis strains from Dolce Cann Global Pty Ltd for medicinal use in treating autism as well as investigating its use in other neurological conditions such as epilepsy and ADHD**
- **The first round of unique Dolce strains has been shipped to ACS Laboratories (TGA approved leading independent Australian cannabis assessment laboratory) for genetic profiling and full spectrum analysis**
- **The Dolce strains to be assessed have shown unusually high levels of cannabinoids CBG, CBC, CBN and CBDV amongst others during its growth cycle. These cannabinoids are hypothesised to benefit people with autism**
- **Following the completion of ACS Laboratories analysis, NTI plans to commence *in-vitro* testing (using human derived cell lines) on the key priority strains targeting autism and other neurological disorders in September 2020**
- **If testing is successful, NTI will partner with a leading Australian university to commence clinical trials utilising both the Dolce cannabis strains and its own proprietary Mente Autism neurofeedback device which analyses brain wave activity**

Neurotech International Limited (ASX: NTI) ("NTI", "Neurotech" or "the Company") is pleased to provide an update on its recently secured option to acquire an exclusive worldwide licence to utilise proprietary cannabis strains from Dolce Cann Global Pty Ltd ('Dolce'). The Company is investigating medicinal use in treating neurological disorders including autism, epilepsy and ADHD, with the first 80 unique Dolce strains transported to ACS Laboratories (a leading independent Australian cannabis lab) for genetic profiling and full spectrum analysis.

Australian-based Dolce has proprietary genetics sourced from 13 rare chemovars and bolstered over the past 20 years by selective breeding targeted for distinct purposes such as cultivation method, climate, yield, phytochemical content and harvested products including flower, seed, fibre or biomass.

Recent profiling of leaf cuttings from 650 seedlings of Dolce landrace genetics evidenced unusually high levels of cannabinoids CBG, CBC, CBN and CBDV among others. Recent studies have indicated the potential for these cannabinoids to target and benefit neurological disorders such as autism.

A key feature of the targeted Dolce strains is plant profiles with less than 0.3% THC (on average). Investigating cannabis research options for children with autism without the potential psychoactive effects of THC is a key component of NTI's investigation of an innovative new project pathway. NTI believes that a combined approach to autism treatment, potentially combining its own clinically proven Mente device with Dolce cannabis strains could lead to innovative new therapy options becoming available as trials progress.



ACS Laboratories will commence profiling and analysis of Dolce's cannabis strains

Following the completion of the profiling and spectrum analysis by ACS Laboratory, NTI plans to commence in-vitro testing (using human derived cell lines) in September 2020. NTI will use results from ACS' analysis to determine the key priority strains to target autism and other neurological disorders.

Neurotech has spent more than five years researching the field of autism and other neurological disorders developing its Mente device, and the Company believes this background will prove integral as it researches the potential use of cannabinoids as a treatment in this field.

The Company looks forward to updating shareholders shortly with the results of the ACS profiling and analysis.

Authority

This announcement has been authorised for release by the Board of Directors of the Company.

Further Information

Mark Davies
Chairman
md@1861capital.com.au
+61 413137887

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 410 667 844

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

www.neurotechinternational.com